BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33099852)

  • 21. Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma.
    Machado-Lopez A; Alonso R; Lago V; Jimenez-Almazan J; Garcia M; Monleon J; Lopez S; Barcelo F; Torroba A; Ortiz S; Domingo S; Simon C; Mas A
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
    Esposito NN; Hunt JL; Bakker A; Jones MW
    Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
    Quade BJ
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
    Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
    PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
    Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
    Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXO3a deregulation in uterine smooth muscle tumors.
    de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
    Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
    Fontanges Q; Dubos P; Lesluyes T; Laizet Y; Velasco V; Meléndez B; D'Haene N; Oliva E; Young RH; Mayeur L; Rebier F; Alamé M; Larmonier C; Devouassoux-Shisheboran M; Arnould L; Soubeyran I; Chakiba C; Floquet A; Babin G; Guyon F; Mery E; Le Guellec S; Noël JC; Croce S; Chibon F
    Genes Chromosomes Cancer; 2024 Mar; 63(3):e23229. PubMed ID: 38481055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raf kinase inhibitor protein expression in smooth muscle tumours of the uterus: a diagnostic marker for leiomyosarcoma?
    Greco S; Pinheiro J; Cardoso-Carneiro D; Giantomassi F; Pellegrino P; Scaglione G; Delli Carpini G; Ciavattini A; Zannoni GF; Goteri G; Martinho O; Ciarmela P
    Reprod Biomed Online; 2024 Jun; 48(6):103816. PubMed ID: 38608337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
    Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
    Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
    de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
    Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors: A Clinicopathologic Analysis of 112 Cases With Emphasis on Potential Diagnostic Pitfalls.
    Lok J; Tse KY; Lee EYP; Wong RWC; Cheng ISY; Chan ANH; Leung CKL; Cheung ANY; Ip PPC
    Am J Surg Pathol; 2021 Sep; 45(9):1179-1189. PubMed ID: 34074809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
    Shanes ED; Friedman LA; Mills AM
    Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
    Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
    Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.